Edition:
United States

OHR Pharmaceutical Inc (OHRP.OQ)

OHRP.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
14 Dec 2017
Change (% chg)

$0.19 (+12.50%)
Prev Close
$1.52
Open
$1.53
Day's High
$1.71
Day's Low
$1.50
Volume
488,523
Avg. Vol
141,441
52-wk High
$1.90
52-wk Low
$0.57

Latest Key Developments (Source: Significant Developments)

Ohr Pharmaceutical files for mixed shelf of up to $250 mln
Friday, 15 Sep 2017 05:14pm EDT 

Sept 15 (Reuters) - Ohr Pharmaceutical Inc :Files for mixed shelf of up to $250 million - SEC filing‍​.  Full Article

OHR Pharmaceutical Q3 loss per share $0.07
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Ohr Pharmaceutical Inc :OHR Pharmaceutical announces fiscal third quarter 2017 earnings.Q3 loss per share $0.07.  Full Article

OHR Pharmaceutical Q2 loss per share $0.21
Thursday, 11 May 2017 04:01pm EDT 

May 11 (Reuters) - OHR Pharmaceutical Inc ::Ohr pharmaceutical announces fiscal second quarter 2017 earnings.Q2 loss per share $0.21.  Full Article

OHR pharmaceutical announces proposed public offering of common stock and warrants
Tuesday, 4 Apr 2017 04:01pm EDT 

OHR Pharmaceutical Inc : OHR Pharmaceutical announces proposed public offering of common stock and warrants .OHR Pharmaceutical- intends to use proceeds from offering for general corporate purposes, including completion, data readout of ongoing clinical study.  Full Article

OHR Pharmaceutical takes actions to suspend activities at San Diego lab facility
Wednesday, 22 Feb 2017 06:08pm EST 

OHR Pharmaceutical Inc : OHR Pharmaceutical- on Feb. 21, 2017, co took actions to suspend activities at its lab facility in San Diego, California- SEC filing . OHR Pharmaceutical- suspension of preclinical activities at lab facility will result in reduction in workforce of about 8 positions at lab facility .OHR Pharmaceutical Inc - reduction in workforce of approximately 8 positions at lab facility, reduction will occur immediately.  Full Article

Ohr pharmaceutical reports Q1 loss per share $0.21
Tuesday, 14 Feb 2017 07:00am EST 

Ohr Pharmaceutical Inc : Ohr Pharmaceutical announces strategic update and fiscal first quarter 2017 earnings . Q1 loss per share $0.21 . For quarter ended december 31, 2016, total operating expenses were approximately $7.0 million . Plan to continue study for currently enrolled patients to evaluate efficacy of squalamine combination therapy . Ohr Pharmaceutical - has paused enrollment in first phase 3 clinical trial of its lead drug candidate squalamine lactate ophthalmic solution, 0.2% ."enrollment pause is not related to any safety issue".  Full Article

OHR Pharmaceutical announces proposed public offering of common stock and warrants
Wednesday, 7 Dec 2016 04:07pm EST 

OHR Pharmaceutical Inc :OHR Pharmaceutical announces proposed public offering of common stock and warrants.  Full Article

OHR Pharmaceutical Q2 loss per share $0.17
Tuesday, 10 May 2016 04:01pm EDT 

Ohr Pharmaceutical Inc : OHR Pharmaceutical Inc says for q2 ended march 31, 2016, total operating expenses were approximately $6.6 million . OHR Pharmaceutical reports second quarter 2016 financial and business results .Q2 loss per share $0.17.  Full Article

BRIEF-Ohr Pharmaceutical files for mixed shelf of up to $250 mln

* Files for mixed shelf of up to $250 million - SEC filing‍​ Source text: (http://bit.ly/2x8VRBB) Further company coverage: